We passionately improve health
Boehringer Ingelheim is a global, research-driven pharmaceutical company embracing many cultures and diverse societies.
THERAPEUTIC AREA
Metabolic
425
million adult people
in the world are living with diabetes, with Type 2 diabetes accounting for 90% of all cases1
About 425 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90 percent of all cases1. This number is projected to increase to 629 million people by 20451. Type 2 diabetes is a chronic, progressive condition and long-term complications include stroke, heart attack and cardiovascular death as well as diabetic kidney disease, retinopathy, arm and leg amputations and autonomic neuropathy. In addition to the now marketed products from our own R&D, we are also focused on cardiometabolic indications with a high unmet medical need.
Learn more
1 Diabetes Atlas 8th edition 2017, International Diabetes Federation. http://www.diabetesatlas.org (link is external) (accessed Apr 2018)
Learn more
Cardiovascular
Cardiovascular disease
including
heart disease
and stroke
is a major
global health concern and the leading cause of death and disability worldwide1
Cardiovascular disease, including heart disease and stroke, is a major global health concern and the leading cause of death and disability worldwide1. At Boehringer Ingelheim we address unmet medical need by providing innovative treatments that improve the care of patients suffering from a range of cardiovascular conditions including irregular heartbeat (atrial fibrillation), stroke, blood clots in deep veins or lungs (deep vein thrombosis or pulmonary embolism), high blood pressure (hypertension) or heart attack (myocardial infarction).
Learn more
1 Vilahur G et al. Eur Heart J Suppl 2014; 16(Suppl_A): A7-A11.
Learn more
Respiratory
Boehringer Ingelheim
has over 90 years
of heritage
in managing
respiratory disease
Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life
Boehringer Ingelheim has over 90 years of heritage in managing respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life.
Learn more
Learn more